Navigation Links
Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
Date:8/14/2008

PRINCETON, N.J., Aug. 14 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, reported unaudited financial results for the third fiscal quarter ended June 30, 2008. Pharmasset reported a net loss attributable to common stockholders of $15.0 million, or a loss per share of $0.69 for the quarter ended June 30, 2008, as compared to a net loss attributable to common stockholders of $7.1 million, or a loss per share of $0.40 per share for the same period in 2007.

Revenues were $0.5 million during the quarters ended June 30, 2008 and 2007 and reflect amortization of up-front and subsequent collaborative and license payments received from Roche previously recorded as deferred revenue. Total costs and expenses for the quarter ended June 30, 2008 were $15.0 million, as compared to $7.1 million for the same period in 2007. The $7.9 million increase in total costs and expenses during the quarter ended June 30, 2008 was primarily due to a $5.8 million increase in Phase 3 clinical trial expenses to support registration of clevudine for the treatment of chronic hepatitis B virus (HBV) infection, a $1.0 million increase in compensation expense resulting from increased headcount, a $0.4 million increase in new drug discovery expenses, and a $0.7 million increase in marketing and other administrative expenses. Investment income decreased to $0.2 million during the quarter ended June 30, 2008 from $0.7 million in the quarter ended June 30, 2007, primarily on lower rates of return on invested balances. Interest expense increased to $0.7 million during the quarter ended June 30, 2008 from $0.0 million in the yea
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
2. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
3. Pharmasset Receives Notice of Allowance
4. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
5. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
6. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
9. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
10. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
11. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Today, Wall Street Reports announced new ... ), Health Management Associates Inc. (NYSE: HMA ), ... Inc. (NASDAQ: ISIS ), and Trius Therapeutics Inc. ... charge - including full price targets, industry analysis and analyst ... Inc. Research Report On June 7, 2013, Gilead ...
(Date:6/18/2013)... , June 18, 2013 Apama ... on the development of next-generation atrial fibrillation technologies, ... 8295902 by the US Patent and Trademark Office ... low profile electrode assemblies for use on expandable ... or other surgical procedures. "We are ...
(Date:6/17/2013)... June 17, 2013 Velplex, LLC announced this ... technology platform that connects buyers and sellers of ... industry leader. Why? It,s because the ... intimately familiar with the dental industry. They have 50 ... have diligently worked to negotiate some of the best ...
Breaking Medicine Technology:Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6TopProdeals.com Rises to Top as Discount Dental Supply Leader 2
(Date:6/18/2013)... 18, 2013 Seven-year-old Riley Salz of ... autism. He receives 40 hours a week of applied ... from the Center for Autism and Related Disorders (CARD). ... 2008, and has experienced remarkable progress, including learning to ... environment. Riley’s personal journey through autism is now featured ...
(Date:6/18/2013)... has shown that cancer cells have a much different ... Now, scientists at The University of Texas at Dallas ... new strategy to combat lung cancer. , In an ... PLOS ONE , UT Dallas researchers compared the metabolic ... cells taken from the same patient. , They ...
(Date:6/18/2013)... at Case Western Reserve University,s College of Arts ... made available avatarsvirtual patientsto train speech-language pathologists. ... to evaluate speech-language disorders to practice using an ... because a diagnosis doesn,t have to be made ... studying to become speech-language pathologists have previously relied ...
(Date:6/18/2013)... More than 1.1 million people in the U.S. ... the Centers for Disease Control and Prevention (CDC). Of those, ... of National HIV Testing Day on June 27, Allsup, a ... representation, the CDC and other organizations are raising awareness of ... about 50,000 new HIV infections each year. Along with developing ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 The Elizabeth ... of State and the U.S. President’s Emergency Plan for ... and celebrate significant new milestones in the global effort ... John Kerry announced that as of June 2013, one ... PEPFAR support. Since PEPFAR’s inception in 2003, EGPAF ...
Breaking Medicine News(10 mins):Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 3Health News:UT Dallas study suggests new approach to fight lung cancer 2Health News:UT Dallas study suggests new approach to fight lung cancer 3Health News:SimuCase avatars advance speech-language pathology training 2Health News:Allsup Observes National HIV Testing Day June 27 2Health News:Allsup Observes National HIV Testing Day June 27 3Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 2Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 3
... the annual budget that was presented by India’s finance Minster ... growth rate//. If this were to be accomplished, it would ... the entire country. The industrial sector had enabled the country ... reduce the financial deficit from the current 4.1% to 3.8% ...
... .Americans seem to have scared away the sleep bug, and ... led// to people making money over those who are sleepless, ... forty winks! ,Reading the prevailing ‘Sleep’ statistics would ... that Americans have spent about $2.1 billion and about 35 ...
... The initiative to curb rising obesity rates by 2010 will fall ... in this area, according to a recent study// . Though local ... sort out the confusion about the thrust given to this area. ... taken, still there is lots left to be done. Obesity has ...
... President Vladimir Putin ordered his ministry to set up a ... has spread to five regions in southern Russia// . ... Oversight Service to be found affecting areas such as Stavropol, ... said that he would establish a special structure which would ...
... It has been proposed to initiate a HIV/AIDS trial in ... (KEMRI) and Walter Reed Foundation// within the next two months. ... Kericho to work in the tea estates provide adequate diversity ... applied to a large population. Dr. Davy Koech, Director, ...
... researcher, from Wake Forest University School of Medicine said that ... home remedies, such as taking a daily tonic of vinegar ... home remedies, vitamins and minerals. ,The aim of ... alternative medicine (CAM) therapies older adults are using and why. ...
Cached Medicine News:Health News:Annual Budget 2006: Health And Education Sector Receive A Boost 2Health News:HIV/AIDS Vaccine Trial To Be Initiated Soon 2Health News:Inclination of North Carolina’s Elderly Population towards Home Remedie 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: